Lise Jamieson
Lise Jamieson is a leading researcher in the field of HIV prevention and epidemiology. She is known for her work on modeling the impact of new HIV prevention strategies, including the use of long-acting injectables, to reduce new infections, particularly among high-risk populations. Her research aims to inform public health policies and programmatic decisions to effectively combat the HIV epidemic.
Not in the pool (under ¢1).
Recent news mentions
Lise Jamieson headed the study presented at the meeting discussing the allocation of lenacapavir shots.
SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them – The Mail & Guardian
South Africa· 2025-12-02
Lise Jamieson is a modelling scientist at the Health Economics and Epidemiology Research Office at Wits University.
SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch – The Mail & GuardianSouth Africa· 2025-12-01
Lise Jamieson is HE2RO’s lead modeller discussing the distribution of the anti-HIV jab.
The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses? – The Mail & GuardianSouth Africa· 2025-10-20
Lise Jamieson is the lead study author discussing the need for high numbers on the daily HIV prevention pill.
Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill – The Mail & GuardianSouth Africa· 2025-09-29
